Login
Evidence Feed
About
Conferences
New
Diagnostics
New
Top genes
New
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
FGFR2 rearrangement
i
Other names:
FGFR2, BEK, CD332, CEK3, CFD1, ECT1, JWS, K-SAM, KGFR, TK14, TK25, Fibroblast growth factor receptor 2
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
2263
Related biomarkers:
Expression
Mutation
CNA
Fusion
Others
‹
›
Associations
News
Twitter
Trials
Reset Filters
VERI cancer hierarchy
x
x
x
x
FGFR2 rearrangement
Cholangiocarcinoma
FGFR2 rearrangement
Cholangiocarcinoma
futibatinib
Sensitive: A1 - Approval
N Engl J Med - 1 week (New C3)
futibatinib
Sensitive
:
A1
N Engl J Med - 1wk
futibatinib
Sensitive: A1 - Approval
N Engl J Med - 1 week
futibatinib
Sensitive
:
A1
N Engl J Med - 1 week - (New C3)
FGFR2 rearrangement
Cholangiocarcinoma
FGFR2 rearrangement
Cholangiocarcinoma
ICP-192
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
ICP-192
Sensitive
:
C3
ASCO-GI 2023 - 2wk
ICP-192
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
ICP-192
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
FGFR2 rearrangement
Cholangiocarcinoma
FGFR2 rearrangement
Cholangiocarcinoma
TT-00420
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
TT-00420
Sensitive
:
C3
ASCO-GI 2023 - 2wk
TT-00420
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
TT-00420
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
FGFR2 rearrangement
Cholangiocarcinoma
FGFR2 rearrangement
Cholangiocarcinoma
infigratinib
Sensitive: A1 - Approval
infigratinib
Sensitive
:
A1
infigratinib
Sensitive: A1 - Approval
infigratinib
Sensitive
:
A1
FGFR2 rearrangement
Cholangiocarcinoma
FGFR2 rearrangement
Cholangiocarcinoma
pemigatinib
Sensitive: A1 - Approval
pemigatinib
Sensitive
:
A1
pemigatinib
Sensitive: A1 - Approval
pemigatinib
Sensitive
:
A1
FGFR2 rearrangement
Cholangiocarcinoma
FGFR2 rearrangement
Cholangiocarcinoma
FGFR inhibitor
Sensitive: C3 – Early Trials
FGFR inhibitor
Sensitive
:
C3
FGFR inhibitor
Sensitive: C3 – Early Trials
FGFR inhibitor
Sensitive
:
C3
FGFR2 rearrangement
Cholangiocarcinoma
FGFR2 rearrangement
Cholangiocarcinoma
RLY-4008
Sensitive: C3 – Early Trials
RLY-4008
Sensitive
:
C3
RLY-4008
Sensitive: C3 – Early Trials
RLY-4008
Sensitive
:
C3
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login